WEE1 and neoplasm: Additional preclinical work demonstrated that the Wee1 inhibitor AZD1775, alone and in combination with irinotecan or vincristine, led to G2/M phase arrest, increased DNA damage, and had anti-tumor activity against in vivo models of high-risk RMS [138,143].